Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Immucor Blood Compatibility Test for Sickle Cell Trait

NEW YORK (GenomeWeb) – Immucor announced Friday that the US Food and Drug Administration has approved the company's PreciseType HEA test to screen blood donors for sickle cell trait (SCT).

The molecular assay — which detects genes that control the expression of antigens that can appear on the surface of red blood cells — received FDA approval in mid-2014 for evaluating blood compatibility between donors and patients to help prevent transfusion mismatches. With the latest approval, the test can be used to screen for SCT, a condition in which an individual carries one of the two abnormal genes responsible for sickle cell disease.

"The use of PreciseType HEA to screen donor units for patients with sickle cell disease, neonates, or any individual that may require SCT-negative blood provides a great improvement over previously used methods and offers the first FDA-approved molecular method specifically for screening units," Michael Spigarelli, vice president of medical affairs at Immucor, said in a statement.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.